68 件 ・ 関連度順
概要と使いどころ
Identify tumor neoantigens from somatic mutations using pVACtools for personalized cancer immunotherapy. Predict mutant peptides that bind patient HLA and may elicit T-cell responses. Use when identifying vaccine targets or checkpoint inhibitor response biomarkers from tumor sequencing data.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes cfDNA methylation patterns for cancer detection using cfMeDIP-seq or bisulfite sequencing with MethylDackel. Identifies cancer-specific methylation signatures and performs tissue-of-origin deconvolution. Use when using methylation biomarkers for early cancer detection or minimal residual disease.
日本語の概要は準備中です。原文の説明を表示しています。
Statistical analysis for metabolomics data. Covers univariate testing, multivariate methods (PCA, PLS-DA), and biomarker discovery. Use when identifying differentially abundant metabolites or building classification models.
日本語の概要は準備中です。原文の説明を表示しています。
Prepare and validate research-only clinical decision-support evaluation, evidence-profile, cohort, survival, biomarker/model, privacy, and governance artifacts. Use for aggregate or synthetic research documentation and traceability—not patient care or live clinical operation.
日本語の概要は準備中です。原文の説明を表示しています。
Generate professional clinical decision support (CDS) documents for pharmaceutical and clinical research settings, including patient cohort analyses (biomarker-stratified with outcomes) and treatment recommendation reports (evidence-based guidelines with decision algorithms). ...
日本語の概要は準備中です。原文の説明を表示しています。
Designs complete research plans that integrate clinical variables with multi-omics data from a user-provided biomedical direction. Always use this skill whenever a user wants to design, scope, or structure a study that combines clinical variables with transcriptomics, proteomics, metabolomics, epigenomics, or related omics layers for mechanism interpretation, biomarker development, risk stratification, treatment-response analysis, or translational use. It should define the clinical use case, alignment across data layers, feature-reduction and fusion logic, modeling route, mechanism-interpretation layer, validation ladder, and four workload configurations (Lite / Standard / Advanced / Publication+). Never fabricate datasets, accession numbers, sample counts, metadata completeness, platform coverage, literature references, PMIDs, DOIs, or validation status. Always include the mandatory Dataset Disclaimer immediately before any workflow section that mentions datasets or public resources.
日本語の概要は準備中です。原文の説明を表示しています。
Extends a mechanistic or association-level biomedical finding into a staged validation pathway that moves from descriptive evidence toward stronger functional support, mechanistic specificity, and clinical relevance. Use this skill when a user has a pathway, biomarker, cell-state, target, mechanism, or association finding and needs to decide what should be validated next, in what order, and which evidence layers are necessary versus optional. Do not default to maximal validation stacks. Build a structured validation ladder with a primary route, stronger upgrade route, and optional extensions.
日本語の概要は準備中です。原文の説明を表示しています。
Generates complete Mendelian Randomization + single-cell transcriptomics (scRNA-seq) research designs from a user-provided direction. Always use this skill whenever a user wants to design, plan, or build a study combining MR and single-cell data — even if phrased as "help me write a paper on X", "design a bioinformatics study for Y", or "I want to study Z using MR and scRNA". Covers five study patterns (mechanism gene-set, key-cell, candidate-gene reverse validation, exposure-disease-cell triangulation, translational biomarker) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with recommended primary plan, step-by-step workflow, figure plan, validation strategy, minimal executable version, publication upgrade path, and a strictly verified reference literature retrieval layer with real references only.
日本語の概要は準備中です。原文の説明を表示しています。
Plans confounder control, variable adjustment logic, and bias mitigation strategies at the protocol stage for clinical, epidemiologic, translational, observational, and biomarker studies. Always use this skill when a user needs to identify major confounders, decide which variables should or should not be adjusted for, compare matching/stratification/weighting approaches, anticipate selection or measurement bias, or pressure-test a study design before execution. Focus on bias sensing, causal structure awareness, variable-role classification, and critical design review rather than generic statistical advice.
日本語の概要は準備中です。原文の説明を表示しています。
Generates complete conventional non-oncology bioinformatics research designs from a user-provided disease context, process-related gene family or biological theme, and validation direction. Use when a study centers on multi-dataset bulk transcriptome integration, DEG analysis, process-gene intersection, enrichment analysis, GSEA, PPI hub-gene prioritization, TF/miRNA regulatory networks, ROC-based biomarker evaluation, and immune infiltration analysis. Covers five study patterns (process-DEG discovery, enrichment/GSEA interpretation, hub-gene prioritization, regulatory-network and immune interpretation, multi-layer public validation) and always outputs Lite / Standard / Advanced / Publication+ with a recommended primary plan, stepwise workflow, figure plan, validation hierarchy, minimal executable version, publication upgrade path, and strictly verified literature retrieval.
日本語の概要は準備中です。原文の説明を表示しています。
Designs studies for predicting treatment response or resistance in biomedical and clinical research. Always use this skill when the user needs a treatment-response or resistance prediction study blueprint rather than a prognostic biomarker protocol, diagnostic test design, causal treatment-effect estimation, or a completed manuscript. Focus on responder definition, treatment context, baseline comparability, feature integration strategy, model development logic, validation architecture, and interpretation boundaries. Do not invent response rates, cohort size, assay readiness, regimen uniformity, literature support, or validation access.
日本語の概要は準備中です。原文の説明を表示しています。
Refines broad, vague, or aspirational biomedical research objectives into clear, bounded, measurable, executable, and downstream-ready study objective statements. Always use this skill when a user has a general aim such as “explore a mechanism,” “study prognosis,” “investigate biomarkers,” or “look at treatment response,” but the objective is still too broad, non-operational, or too ambiguous to support protocol framing, design selection, analysis planning, or hypothesis design. Never assume that polished wording alone means the objective is actionable. Focus first on objective type, missing operational elements, scope discipline, and downstream-ready formulation.
日本語の概要は準備中です。原文の説明を表示しています。
Designs complete single-cell research plans from a user-provided biomedical direction. Always use this skill whenever a user wants to design, scope, or structure a single-cell study — including disease-focused, mechanism-focused, biomarker-focused, translational, perturbation-inspired, or validation-aware projects. It should define the research question, choose the best-fit study pattern, recommend sample grouping logic, suggest reference datasets as examples only, specify the core analysis modules, propose a validation ladder, and output four workload configurations (Lite / Standard / Advanced / Publication+). Never fabricate datasets, sample metadata, accession numbers, cohort availability, cell-type labels, external validation resources, or literature references. Always include the mandatory Dataset Disclaimer immediately before any workflow section that mentions datasets or public resources.
日本語の概要は準備中です。原文の説明を表示しています。
Use when evaluating diagnostic biomarker performance from case-control expression data with logistic regression and ROC curves, exporting coefficient and AUC tables together with a ROC PDF. NOT for: survival analysis, time-to-event outcomes, multiclass classification, calibration curves, decision-curve analysis, or nomogram construction.
日本語の概要は準備中です。原文の説明を表示しています。
Designs cell-based and animal-based validation plans that translate computational, omics, biomarker, genetic, or clinical findings into experimentally testable validation routes. Always use this skill whenever a user wants to move from an in silico, statistical, or clinical association finding toward wet-lab validation using cell systems, organoid-like systems, xenograft or genetically relevant animal models. It should define the exact claim to test, separate mechanism-testing from association-support and translational-support goals, choose the best-fit model family, specify perturbation strategy, readouts, controls, sequencing of experiments, and four workload configurations (Lite / Standard / Advanced / Publication+) with one recommended primary plan. Never fabricate model availability, reagent availability, species relevance, assay feasibility, phenotype penetrance, expected effect sizes, validation success, or literature references.
日本語の概要は準備中です。原文の説明を表示しています。
Designs complete integrated research plans for bulk transcriptomics, proteomics, metabolomics, and related omics from a user-provided biomedical direction. Always use this skill whenever a user wants to design, scope, or structure a bulk multi-omics or single-omics-plus-clinical study — including disease-focused, mechanism-focused, biomarker-focused, stratification-oriented, or translational projects. It should define the research question, choose the best-fit study pattern, recommend example datasets as reference candidates only, specify the core analysis modules and method choices, propose a validation ladder, and output four workload configurations (Lite / Standard / Advanced / Publication+). Never fabricate datasets, accession numbers, sample counts, metadata completeness, cohort availability, assay coverage, literature references, PMIDs, DOIs, or validation status. Always include the mandatory Dataset Disclaimer immediately before any workflow section that mentions datasets or public resources.
日本語の概要は準備中です。原文の説明を表示しています。
Identify tumor neoantigens from somatic variants with pVACtools (pVACseq/pVACfuse/pVACbind/pVACvector/pVACview) for personalized cancer vaccines and checkpoint biomarkers. Encodes the field's hard truth that binding prediction is the easy, near-solved part and single-digit-percent PPV lives downstream — so it centers clonality/CCF, HLA LOH (the silent invalidator), expression, proximal-variant phasing, agretopicity/foreignness quality, and the predicted->presented->immunogenic validation tiers. Use when nominating vaccine targets, ranking neoantigens, or building a tumor-to-candidate pipeline. Binding details in mhc-binding-prediction; ranking in immunogenicity-scoring.
日本語の概要は準備中です。原文の説明を表示しています。
Plot per-group distributions of continuous data using boxplots, violins, beeswarms, quasirandom jitter, and raincloud plots with sample-size honesty (Weissgerber 2015), KDE-bandwidth awareness, and N-aware encoding choices. Use when comparing distributions across a small number of groups — expression per cluster, biomarker per arm, scores per condition — and the bar-of-mean default is misleading.
日本語の概要は準備中です。原文の説明を表示しています。
Calls microsatellite instability from WES/WGS/targeted-panel with MSIsensor, MSIsensor-pro, MSIsensor-ct (panel-aware), mSINGS, and MANTIS for FDA pembrolizumab MSI-H pan-tumor / Lynch syndrome / dMMR ICI biomarker. Use when stratifying ICI eligibility (Le 2015), pairing MSI with TMB-H (Sha 2020 / Salem 2018), screening Lynch syndrome (universal IHC + MSI), or distinguishing MSI-H tumors from POLE-exo hypermutator with overlapping signatures.
日本語の概要は準備中です。原文の説明を表示しています。
Access NIH Metabolomics Workbench via REST API (4,200+ studies). Query metabolites, RefMet nomenclature, MS/NMR data, m/z searches, study metadata, for metabolomics and biomarker discovery.
日本語の概要は準備中です。原文の説明を表示しています。
Access Human Metabolome Database (220K+ metabolites). Search by name/ID/structure, retrieve chemical properties, biomarker data, NMR/MS spectra, pathways, for metabolomics and identification.
日本語の概要は準備中です。原文の説明を表示しています。
Think and work like an expert Immunotherapy Scientist. Use when a task calls for Immunotherapy Scientist judgment. Reasons from antigen recognition and checkpoint circuits through CAR-T/bispecific design, ASTCT CRS/ICANS grading, flow cytometry release CQAs, iRECIST response assessment, COMPASS/TIDE biomarker modeling, and JACIE/FACT IEC accreditation while treating antigen escape, pseudoprogression, tonic signaling, and step-up CRS as first-class failure modes.
日本語の概要は準備中です。原文の説明を表示しています。
Think and work like an expert Cancer Biologist. Use when a task calls for Cancer Biologist judgment. Reasons from hallmark capabilities, clonal evolution, and TME context; separates driver from passenger, cell-autonomous from stromal mechanisms, and 2D artifacts from PDO/PDX-validated dependencies using TCGA, DepMap, OncoKB, and REMARK-grade biomarker logic.
日本語の概要は準備中です。原文の説明を表示しています。
Plot per-group distributions of continuous data using boxplots, violins, beeswarms, quasirandom jitter, and raincloud plots with sample-size honesty (Weissgerber 2015), KDE-bandwidth awareness, and N-aware encoding choices. Use when comparing distributions across a small number of groups — expression per cluster, biomarker per arm, scores per condition — and the bar-of-mean default is misleading.
日本語の概要は準備中です。原文の説明を表示しています。